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Introduction: This randomized, double-blind, phase II study evaluated the pharmacodynamics, safety and tolerability
of ISIS 329993 (ISIS-CRPRx), an antisense oligonucleotide, in patients with active rheumatoid arthritis (RA).
Methods: Patients with active RA of at least six months duration were randomized into three cohorts to receive
ISIS-CRPRx (100 mg, 200 mg or 400 mg) or placebo (3 active:1 placebo within each cohort) via subcutaneous (SC)
injection on Days 1, 3, 5 and 8 and then once weekly for the next 11 weeks. The effects of study treatment on
high-sensitivity C-reactive protein (hs-CRP) level were evaluated. An exploratory analysis on disease activity was
assessed via the American College of Rheumatology 20% improvement criteria (ACR20). Safety was evaluated via
adverse events and laboratory measures.
Results: Fifty-one patients received one of the following treatments: ISIS-CRPRx 100 mg, n = 12; 200 mg, n = 13,
400 mg, n = 14; placebo n = 12. In the ISIS-CRPRx treatment groups there were dose-dependent reductions in
hs-CRP. At Day 36 the mean percent change from baseline was: placebo: −14.4%; ISIS-CRPRx 100 mg: −19.5%;
200 mg: −56.6% and 400 mg: −76.7%, (P = 0.0015 placebo compared to 400 mg). There were no differences
between treatment groups and placebo in the ACR20 at Day 36 or Day 92. There were no serious infections and
no elevations in liver function tests, lipids, creatinine or other lab abnormalities related to ISIS-CRPRx.
Conclusions: In this study, ISIS-CRPRx selectively reduced hs-CRP in a dose-dependent manner, and was
well-tolerated in patients with RA. Its utility as a therapy in RA remains unclear.
Trial registration: Clinicaltrials.gov NCT01414101. Registered 21 July 2011.Introduction
Studies of patients with rheumatoid arthritis (RA) docu-
ment a correlation between C-reactive protein (CRP)
blood concentration and worsening of RA symptoms. In-
flammation in RA is closely related to the production of
CRP and proinflammatory cytokines [1]. Levels of CRP
correlate closely with changes in inflammation/disease ac-
tivity, radiological damage and progression, and functional
disability [1]. Although CRP is considered to be a marker
of inflammation in RA, it may also function in the promo-
tion of inflammation through complement activation [2].* Correspondence: shughes@isisph.com
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stated.CRP, and in particular the high-sensitivity CRP (hs-CRP)
assay, has been shown to be more closely associated with
disease activity variables than erythrocyte sedimentation
rate (ESR) [3].
ISIS 329993 (ISIS-CRPRx) is an antisense drug targeted
to human CRP. ISIS-CRPRx has been tested in a rodent
model of RA (that is, CRP transgenic mice with collagen-
induced arthritis) and was shown to improve the clinical
signs of arthritis [4]. Further, in a previously conducted
clinical study in healthy human volunteers (N = 8), whose
blood hs-CRP levels ranged from ≥2 to 10 mg/L on two
qualifying examinations within a two-week period, treat-
ment with ISIS-CRPRx achieved significant hs-CRP lower-
ing [4]. The next step in the clinical development process. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ducing hs-CRP in patients with a chronic inflammatory
disease, RA.
The objectives of this clinical study were to evaluate
the pharmacodynamics, safety and tolerability of ISIS-
CRPRx in patients with active RA.Methods
This Phase II, international, multi-center, double-blind,
placebo-controlled, parallel group study in patients with
RA was conducted at three sites in Canada and ten sites in
Russia with enrollment beginning on 3 October 2011 and
ending on 18 December 2012. The Institutional Review
Board at each site approved the study protocol and the in-
formed consent (see Additional file 1 for details of the eth-
ical bodies). This study was performed in accordance with
globally accepted standards of Good Clinical Practice (as
defined in the International Conference on Harmonisation
E6 Guidelines for Good Clinical Practice, 1 May 1996), and
in agreement with the Declaration of Helsinki and in keep-
ing with local regulations. Prior to screening, all subjects
provided written informed consent. The trial was regis-
tered with clinicaltrials.gov (www.clinicaltrials.gov) [Iden-
tification number: NCT01414101].Patients
Patients (18 to 75 years of age) with active RA, as de-
fined by the American Rheumatism Association 1987 re-
vised criteria [5], for at least six months, and a function
Class I-III classified according to the American College
of Rheumatology 1991 criteria were enrolled [6]. Patients
were required to have hs-CRP of ≥5 mg/L at screening
(upper limit of normal >3 mg/L) with at least six swollen
joints and at least six tender joints, based on a 28-joint
count. All patients had received at least three months of
methotrexate therapy at a stable dose of ≥10 mg unless
they could not tolerate that dose. Methotrexate, at stable
dose, was continued throughout the study. Other concomi-
tant disease-modifying antirheumatic drugs (DMARDs),
non-steroidal anti-inflammatory drugs (NSAIDs) and pred-
nisone at 10 mg daily or less were stable prior to and dur-
ing the study.Interventions
Eligible patients were randomized in an equal ratio to
one of the three dose cohorts (100 mg ISIS-CRPRx or
placebo; 200 mg ISIS-CRPRx or placebo; or 400 mg ISIS-
CRPRx or placebo). Within each dose cohort, patients
were randomized to receive ISIS-CRPRx or placebo in a
3:1 ratio. Enrolled patients received subcutaneous (SC)
injections of ISIS-CRPRx or placebo on Days 1, 3, 5 and
8 and then once weekly for the next 11 weeks.Outcomes
Pharmacodynamic
The effects of treatment with ISIS-CRPRx versus placebo
on hs-CRP and other markers of inflammation (for
example, ESR, serum amyloid A (SAA), interleukin-6
(IL-6), tumor necrosis factor alpha (TNF-α), tumor ne-
crosis factor receptor 1 (TNF-RI), tumor necrosis factor
receptor 2 (TNF-RII), fibrinogen and complement) were
evaluated throughout the study. During screening, pa-
tients had to have at least two hs-CRP measurements
taken at least one week apart and no more than one
week prior to initiation of dosing and the average of
these values was used as the subjects’ baseline hs-CRP
level. Patient hs-CRP levels and other markers of inflam-
mation were assessed during the treatment and post-
treatment evaluation period at regular intervals.
Exploratory activity in RA
The American College of Rheumatology 20% improve-
ment criteria (ACR20) is a widely accepted index of im-
provement in RA [7] that refers to an improvement of at
least 20% in a composite measure of the disease. ACR20
response criteria were assessed at baseline on Day 1 prior
to dosing and on Day 36 and Day 92. Disease activity was
also assessed using the Disease Activity Score Activity
Score Calculator for Rheumatoid Arthritis using the ESR
(DAS28-ESR) [8]. DAS28-ESR criteria were assessed at
baseline on Day 1 prior to dosing and on Day 36 and Day
92. Patients were considered to be in remission if they had
a score of less than 2.6 on the DAS28-ESR.
Safety
Safety was assessed via adverse events (defined as an ad-
verse event that occurred on or after the first dose of




It was estimated that the standard deviation of the per-
cent change of hs-CRP was approximately 40% based on
the results of a Phase I study [9]. With 12 subjects in each
treatment group, the study was designed to have approxi-
mately 74% power to detect a 45% difference in hs-CRP
between the treated group and the placebo group, assum-
ing the treated group would have a 50% reduction in hs-
CRP while the control group would have a 5% reduction.
An alpha level of 0.05 was utilized.
Randomization
Eligible subjects were randomized equally to one of three
dose cohorts (ratio = 1:1:1). Each dose cohort was to con-
sist of 16 subjects. Within each dose cohort, subjects were
randomized to receive ISIS-CRPRx or placebo in a 3:1 ratio,
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study drug administration (ISIS-CRPRx or placebo) using
an automated system.
Blinding
The study was blinded with respect to the treatment
allocation for subjects, investigators, coordinators and
sponsor. The dose cohort was not blinded.
Statistical methods
The safety population consisted of all patients who were
randomized and received at least one dose of study drug.
The per protocol population consisted of all subjects
who were randomized and received at least 60% of doses
(≥9 doses), completed the Day 92 or early termination
evaluations and did not have any clinically significant
protocol deviations.
Demographic and baseline characteristic information
was summarized descriptively for each treatment group.
Pharmacodynamic endpoints were summarized using the
per protocol population. The effects of treatment (ISIS-
CRPRx versus placebo) on hs-CRP and other markers of
inflammation were evaluated at multiple time points after
dosing. Baseline hs-CRP was determined as the average of
all of the values during the screening period, prior to
dosing on Day 1. In addition, the effects of treatment
(ISIS-CRPRx versus placebo) were evaluated on the pro-
portion of subjects achieving clinical improvement in
RA disease activity at Day 36 and Day 92 compared to




A total of 51 subjects were randomized in this study (12
placebo, 12 ISIS-CRPRx 100 mg, 13 ISIS-CRPRx 200 mg
and 14 ISIS-CRPRx 400 mg) and 41 subjects completed
the treatment (11 placebo, 11 ISIS-CRPRx 100 mg, 9 ISIS-
CRPRx 200 mg and 10 ISIS-CRPRx 400 mg) (Additional
file 2). Demographics and baseline characteristics were
similar across the treatment groups (Table 1).
Medication exposure
The mean number of doses that patients received was
similar across treatment groups in the per protocol popu-
lation (14.2 placebo, 15 ISIS-CRPRx 100 mg, 14.9 ISIS-
CRPRx 200 mg and 14.6 ISIS-CRPRx 400 mg) as was the
mean number of days of treatment (81 placebo, 86 ISIS-
CRPRx 100 mg, 86 ISIS-CRPRx 200 mg and 85 ISIS-CRPRx
400 mg).
Pharmacodynamics
Robust, durable, selective and dose dependent reductions
of hs-CRP were observed by Day 36, with the effectspreserved at Day 92 (Table 2 and Additional file 3). There
was a large placebo response (45% reduction at Day 92)
observed in hs-CRP. There were no meaningful differ-
ences or trends between placebo and the ISIS-CRPRx
treatment in the other markers of inflammation (that is,
fibrinogen, SAA, TNF-α, cytokine IL-6, TNF-RI and
TNF-RII) at either Day 36 or Day 92. Mean baseline,
Day 36 and 92 results are presented in Table 2 for TNF-α,
IL-6 and SAA.
Exploratory disease activity
As compared with placebo, there were no statistically
significant effects seen with ISIS-CRPRx on disease symp-
toms as assessed via ACR20, ACR50 or DAS28-ESR
(Table 2) at Day 36 or Day 92.
Safety
ISIS-CRPRx was generally safe and well tolerated with no
serious infections due to treatment. There were similar
numbers of patients who reported treatment emergent
adverse events (TEAEs) across the treatment groups (8/
12 placebo, 7/12 ISIS-CRPRx 100 mg, 11/13 ISIS-CRPRx
200 mg and 12/14 ISIS-CRPRx 400 mg) (Table 3). There
were a similar number of infections reported in each group
(Table 3). Infections were reported as mostly mild in sever-
ity with only a few reported as moderate (Table 3).
There were seven patients who discontinued treatment
either due to TEAEs or meeting the requirements for
one of the stopping rules. One patient on ISIS-CRPRx
200 mg discontinued treatment due to fatal pulmonary
edema which also met the criteria for a serious adverse
event (SAE). This patient had known atherosclerotic vas-
cular disease. The investigator rated this as possibly re-
lated to study drug. Two patients discontinued treatment
due to worsening of RA symptoms. One was on ISIS-
CRPRx 200 mg and the other was on ISIS-CRPRx 400 mg.
Three patients (one placebo, one ISIS-CRPRx 200 mg and
one ISIS-CRPRx 400 mg) met the protocol pre-specified
stopping criteria for renal function (that is, serum creatin-
ine (Cr) increase >0.2 mg/dL). However, the absolute
serum Cr levels remained within the normal limits for all
of these patients. One patient on ISIS-CRPRx 200 mg dis-
continued treatment due to an exacerbation of chronic
calculous cholecystitis although this was considered un-
likely related to study drug by the investigator.
Discussion
ISIS 329993 (ISIS-CRPRx) is a novel approach to redu-
cing the inflammatory marker CRP and to potentially
down regulate inflammation. As an antisense drug tar-
geting human CRP it was hypothesized that ISIS-CRPRx
should be non-immunosuppressant and it, therefore,
might be a valuable adjunct to standard DMARDs, or
even biologic DMARDs. Previous studies of ISIS-CRPRx
Table 1 Baseline demographics and disease characteristics
Demographics (Safety Population) Placebo ISIS-CRPRx ISIS-CRPRx ISIS-CRPRx
100 mg 200 mg 400 mg
Number = 12 Number = 12 Number = 13 Number = 14
Race
White, number (%) 12 (100) 12 (100) 13 (100) 14 (100)
Sex
Female, number (%) 12 (100) 9 (75) 8 (61.5) 13 (92.9)
Age, years, mean (SD) 64.1 (4.25) 56.08 (13.14) 58.69 (9.81) 62.93 (7.97)
Weight, kg, mean (SD) 72.29 (13.39) 74.05 (19.81) 73.75 (16.43) 72.19 (13.39)
BMI, kg/m2, mean (SD) 28.36 (4.97) 27.27 (5.04) 25.78 (4.93) 26.84 (3.63)
Duration of RA since 1st diagnosis, years, mean (SD) 18.6 (15.8) 6.3 (8.1) 8.8 (7.8) 18.3 (12.4)
ACR Functional Class, number (%)
Class I 1 (8.3) 1 (8.3) 0 1 (7.1)
Class II 6 (50.0) 8 (66.7) 7 (53.8) 7 (50.0)
Class III 5 (41.7) 3 (25.0) 6 (46.2) 6 (42.9)
Morning stiffness, minutes, mean (SD) 61.7 (29.3) 98.3 (97.5) 90.4 (59.0) 106.4 (75.9)
Disease Characteristics (Per Protocol Population) Number = 11 Number = 10 Number = 8 Number = 11
Westergren ESR, mm/hour, mean (SD) 41.0 (27.7) 47.6 (27.3) 37.4 (14.0) 44.5 (31.1)
hsCRP, mg/L, mean (SD) 22.4 (18.1) 29.7 (29.0) 35.2 (36.4) 19.3 (13.6)
Swollen joint count, mean (SD) 12.5 (5.6) 9.7 (6.4) 9.8 (4.5) 8.3 (2.2)
Tender joint count, mean (SD) 17.6 (8.3) 15.9 (8.0) 14.8 (7.5) 14.1 (5.7)
DAS28-ESR, mean (SD) 6.66 (0.6) 6.36 (1.1) 6.27 (0.7) 6.23 (0.9)
HAQ, mean (SD) 1.67 (0.6) 1.50 (0.7) 1.58 (0.6) 1.73 (0.6)
Patient’s pain assessment, mean (SD) 66.82 (16.4) 54.50 (16.6) 59.75 (13.2) 61.55 (18.4)
Patient’s global assessment of disease activity, mean (SD) 2.64 (0.7) 2.30 (0.7) 2.38 (0.5) 2.45 (0.5)
Physician’s global assessment of disease activity, mean (SD) 2.18 (0.4) 2.10 (0.7) 2.50 (0.5) 2.36 (0.5)
ACR, American College of Rheumatology; BMI, body mass index; DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate; ESR, erythrocyte sedimentation
rate; HAQ, Health Assessment Questionnaire; hsCRP, high sensitivity C-reactive protein; percentage calculated as 100 × n/N; SD, standard deviation.
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with collagen-induced arthritis) demonstrated improve-
ment in the clinical signs of arthritis [4]. Subsequently,
initial clinical studies in healthy human volunteers dem-
onstrated that treatment with ISIS-CRPRx achieved sig-
nificant hs-CRP lowering [4]. Before embarking on a
large RA study to definitively address the question of
clinical improvement in symptoms and signs, it was
decided to first explore whether this approach would
reproducibly decrease hs-CRP in RA patients and to as-
sess its potential impact on other markers of inflamma-
tion. Given the results of this study, ISIS-CRPRx has
demonstrated that the antisense oligonucleotide plat-
form can selectively reduce circulating levels of hs-CRP.
The results at 36 days demonstrate separation between
dosing cohorts with respect to percent change in hs-
CRP and achieved statistical significance at the highest
dose, with a 76.7% reduction in hs-CRP in the ISIS
CRPRx 400 mg arm compared with a 14.4% reduction in
the placebo arm at Day 36 (P = 0.0015). However, by92 days this response does not appear as statistically
robust given the significant decreases in hs-CRP seen in
the placebo group. It is unclear what drove the de-
creases in hs-CRP in the placebo group but it could be
speculated that it was in part regression to the mean,
and possibly related to increased compliance with back-
ground regimens that can also be seen in clinical trials
as a consequence of closer follow-up.
It remains unclear whether ISIS-CRPRx is truly anti-
inflammatory in an active human disease state. Despite
the encouraging data in the animal models, there was lit-
tle change in the other inflammatory markers studied in
this trial including ESR, SAA, IL-6, TNF-α, fibrinogen
and complement. This invites the question as to whether
inflammation was down regulated or whether the drug
was simply effective at blocking a surrogate marker of
inflammation. Additionally, the exploratory endpoints of
ACR20/50 and DAS28-ESR were frankly difficult to in-
terpret in the setting of such small numbers and such
high placebo response rates. That said, the reductions
Table 2 Inflammation markers and disease activity outcomes (per protocol population)
Placebo ISIS-CRPRx ISIS-CRPRx p-value ISIS-CRPRx
Nimber = 11 100 mg 200 mg 400 mg
Number = 10 Number = 8 Number = 11
INFLAMMATION MARKERS P-valuea P-valuea P-valuea
hs-CRP (mg/L) Number = 11 Number = 10 Number = 8 Number = 11
Baseline, mean (SD) 22.4 (18.1) 29.7 (29.0) 0.97 35.2 (36.4) 0.24 19.3 (13.6) 0.65
Number = 10 Number = 10 Number = 8 Number = 11
Day 36, mean (SD) 16.4 (12.3) 16.9 (16.2) 0.85 19.1 (25.9) 0.57 4.26 (4.2) 0.004
Day 36, mean change from baseline (SD) −6.8 (15.6) −12.8 (20.9) 0.85 −16.1 (12.1) 0.15 −15.0 (11.5) 0.07
Day 36, percentage change from
baseline, mean (SD)
−14.4 (66.3) −19.5 (63.6) 0.97 −56.6 (26.2) 0.10 −76.7 (16.4) 0.002
Number = 11 Number = 10 Number = 8 Number = 11
Day 92, mean (SD) 10.8 (10.5) 15.0 (19.1) 0.93 12.0 (10.7) 0.89 5.6 (5.2) 0.22
Day 92, mean change from baseline (SD) −11.6 (17.3) −14.7 (18.9) 0.81 −23.2 (28.2) 0.13 −13.7 (13.3) 0.80
Day 92, percentage change from baseline,
mean (SD)
−44.5 (60.2) −33.8 (82.3) 0.86 −66.9 (23.0) 0.49 −64.4 (38.6) 0.19
P-valuea P-valuea P-valuea
TNF-α (pg/mL) Number = 11 Number = 10 Number = 8 Number = 11
Baseline, mean (SD) 15.6 (0.0) 15.6 (0.0) 1.00 15.6 (0.0) 1.00 15.6 (0.0) 1.00
Number = 10 Number = 10 Number = 8 Number = 11
Day 36, mean (SD) 15.6 (0.0) 15.6 (0.0) 1.00 15.6 (0.0) 1.00 15.6 (0.0) 1.00
Number = 11 Number = 10 Number = 8 Number = 11
Day 92, mean (SD) 15.6 (0.0) 15.6 (0.0) 1.00 15.9 (0.8) 0.42 16.0 (1.4) 1.00
P-valuea P-valuea P-valuea
IL-6 (pg/mL) Number = 10 Number = 9 Number = 8 Number = 11
Baseline, mean (SD) 24.6 (20.3) 46.2 (45.3) 0.24 35.7 (32.9) 0.57 25.6 (26.1) 0.92
Number = 10 Number = 10 Number = 7 Number = 11
Day 36, mean (SD) 21.4 (19.8) 35.7 (32.5) 0.68 27.9 (21.6) 0.67 28.3 (42.1) 0.97
Number = 11 Number = 10 Number = 7 Number = 11
Day 92, mean (SD) 30.3 (41.6) 32.1 (28.1) 0.65 83.1 (142.6) 0.20 53.5 (62.3) 0.30
P-valuea P-valuea P-valuea
Serum Amyloid A (mg/L) Number = 11 Number = 10 Number = 8 Number = 11
Baseline, mean (SD) 75.5 (167.4) 67.9 (85.4) 0.92 171.1 (255.1) 0.35 35.5 (44.4) 0.62
Number = 10 Number = 10 Number = 8 Number = 11
Day 36, mean (SD) 33.9 (41.2) 45.8 (38.4) 0.44 105.1 (192.2) 0.24 48.3 (86.4) 0.67
Number = 11 Number = 10 Number = 8 Number = 11
Day 92, mean (SD) 24.8 (30.0) 42.6 (39.2) 0.28 96.8 (112.0) 0.03 88.9 (98.9) 0.07
DISEASE ACTIVITY OUTCOMES
ACR P-valueb P-valueb P-valueb
Day 36, number (% of responders) Number = 10 Number = 10 Number = 8 Number = 11
ACR20% by hs-CRP 2 (20.0) 3 (30.0) 1.000 0 0.477 4 (36.4) 0.635
ACR20% by ESR 2 (20.0) 3 (30.0) 1.000 0 0.477 3 (27.3) 1.000
ACR50 by hs-CRP 1 (10.0) 2 (20.0) 1.000 0 1.000 1 (9.1) 1.000
ACR50 by ESR 0 2 (20.0) 0.474 0 0
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Table 2 Inflammation markers and disease activity outcomes (per protocol population) (Continued)
P-valueb P-valueb P-valueb
Day 92, number (% of responders) Number = 11 Number = 10 Number = 8 Number = 11
ACR20 by hs-CRP 6 (54.5) 5 (50.0) 1.000 1 (12.5) 0.147 4 (36.4) 0.392
ACR20 by ESR 6 (54.5) 4 (40.0) 0.670 1 (12.5) 0.147 4 (36.4) 0.392
ACR50 by hs-CRP 2 (18.2) 2 (20.0) 1.000 0 0.485 3 (27.3) 1.000
ACR50 by ESR 1 (9.1) 2 (20.0) 0.586 0 1.000 2 (18.2) 1.000
DAS28-ESR P-valuea P-valuea P-valuea
Number = 11 Number = 10 Number = 8 Number = 11
Baseline, mean (SD) 6.7 (0.6) 6.4 (1.1) 0.4298 6.3 (0.7) 0.3352 6.2 (0.9) 0.2489
Number = 10 Number = 10 Number = 8 Number = 11
Day 36, mean (SD) 6.2 (1.1) 5.4 (1.5) 0.1097 5.8 (1.1) 0.4974 5.2 (1.2) 0.0572
Day 36, mean change from baseline (SD) −0.5 (0.6) −1.0 (0.9) 0.2176 −0.4 (0.7) 0.8286 −1.0 (0.8) 0.0986
Day 36, percentage change from baseline,
mean(SD)
−8.0 (10.7) −16.3 (16.1) 0.1431 −7.1 (11.2) 0.8968 −16.8 (12.7) 0.1321
Number = 11 Number = 10 Number = 8 Number = 11
Day 92, mean (SD) 5.3 (1.6) 5.2 (1.5) 0.8711 5.6 (1.1) 0.7164 5.1 (1.2) 0.6880
Day 92, mean change from baseline (SD) −1.3 (1.2) −1.1 (1.1) 0.6833 −0.7 (0.7) 0.2422 −1.1 (1.3) 0.6887
Day 92, percentage change from baseline,
mean (SD)
−20.7 (19.7) −17.5 (18.1) 0.6873 −11.7 (11.1) 0.2982 −16.9 (21.2) 0.6237
aP-values calculated using a pairwise comparison between active treatment and placebo using the analysis of variance or Wilcoxon Rank Sum test; bP-values
calculated using a pairwise comparison between active treatment and placebo using the Fisher’s Exact Test or Chi-square test. ACR, American College of Rheumatology;
DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR = 0.56*square root oftender joint count + 0.28* square root of swollen joint count +
0.014*subject assessment of pain + 0.70*ln(ESR)); ESR, erythrocyte sedimentation rate; hs-CRP, high sensitivity C-reactive protein; SD, standard deviation.
Table 3 Adverse events (safety population)
Placebo ISIS-CRPRx ISIS-CRPRx ISIS-CRPRx
100 mg 200 mg 400 mg
Number = 12 Number = 12 Number = 13 Number = 14
Overall adverse events, n (%) 8 (66.7) 7 (58.3) 11 (84.6) 12 (85.7)
Adverse events with incidence 10% or greater in all ISIS-CRPRx
dosed patients by treatment excluding adverse events at
the injection site,
Rheumatoid arthritis, number (%) 1 (8.3) 1 (8.3) 2 (15.4) 2 (14.3)
Blood creatinine increased, number (%) 1 (8.3) 2 (16.7) 1 (7.7) 1 (7.1)
Adverse events-infections, number (%) 4 (33.3) 1 (8.3) 2 (15.4) 4 (28.6)
Nasopharyngitis, number (severity) 1 (moderate) 1 (mild) 1 (mild) 1 (moderate)
Upper respiratory infection, number (severity) 0 0 0 1 (mild)
Rhinitis, number (severity) 1 (mild) 0 0 0
Bronchitis, number (severity) 2 (moderate) 0 1 (moderate) 0
Urinary tract infection/cystitis, number (severity) 0 1 (mild) 1 (moderate) 2 (mild)
Foot infection, number (severity) 0 0 0 1 (mild)
Pyelonephritis chronic, number (severity) 1 (mild) 0 0 0
Adverse events-injection site reactions
Overall, number (%) 0 3 (25) 3 (23) 3 (21)
Erythema, number (%) 0 3 (25) 3 (23) 3 (21)
Pruritus, number (%) 0 1 (8) 0 0
Pain, number (%) 0 0 0 1 (7)
Swelling, number (%) 0 0 0 1 (7)
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not of sufficient magnitude to offer significant benefit
over the currently available drugs for treatment of RA.
It appeared that ISIS-CRPRx was well tolerated in a
population with active autoimmune/inflammatory disease.
However, the small sample size limits the ability to detect
uncommon safety signals.
There were some limitations to this study, most not-
ably the overall size and powering together with the very
large placebo response rate limited the conclusions that
could be drawn. However, even with a small sample size,
the lack of any discernible effect on other markers of in-
flammation coupled with the very modest clinical changes
make it unlikely that ISIS-CRPRx will be an adequately
effective drug for treatment of rheumatoid arthritis
when compared with other currently available and ex-
perimental therapies.Conclusions
In this study, ISIS-CRPRx selectively reduced hs-CRP in
a dose-dependent manner, and was well-tolerated in pa-
tients with RA. Its utility as a therapy in RA remains un-
clear. There may be other chronic inflammatory conditions
in which CRP has a causative or contributory role; so add-
itional studies in other diseases may be warranted given
the tolerability of ISIS-CRPRx, the lack of obvious im-
mune suppression and the potential for combination
with other agents.Additional files
Additional file 1: Listing of Ethics Committees and Institutional
Review Boards (IRB).
Additional file 2: Flow of patients through study. CONSORT patient
disposition diagram.
Additional file 3: Change in hs-CRP by treatment group. Panel A
shows mean absolute change from baseline (mg/L) in hs-CRP at Day 36
and Day 92 by dose group. Panel B shows mean percent change from
baseline in hs-CRP at Day 36 and Day 92 by dose group).
Abbreviations
ACR20: American College of Rheumatology 20% improvement criteria;
ACR50: American College of Rheumatology 50% improvement criteria;
Cr: creatinine; CRP: C-reactive protein; DAS28-ESR: Disease Activity Score
Activity Score Calculator for Rheumatoid Arthritis using the ESR;
DMARD: disease-modifying antirheumatic drugs; ESR: erythrocyte
sedimentation rate; Hs-CRP: high sensitivity C-reactive protein assay;
NSAIDs: non-steroidal anti-inflammatory drugs; RA: rheumatoid arthritis;
SAA: serum amyloid A; TEAEs: treatmemt emergent adverse effects;
TNF-R2: tumor necrosis factor receptor 2; TNF-RI: tumor necrosis factor
receptor 1; TNF-α: tumor necrosis factor alpha.
Competing interests
Marshelle S. Warren, Steven G. Hughes, Walter Singleton, and Mason
Yamashita are employees of ISIS Pharmaceuticals, Inc. Marshelle S. Warren,
Steven G. Hughes, Walter Singleton, and Mason Yamashita have no
non-financial competing interests. Mark C. Genovese declares that he
has no competing interests.Authors’ contributions
MSW was involved in the execution of the study, interpretation of the data,
drafting the manuscript as well as review and critique of the manuscript. SH
was involved in the conception, organization and execution of the study,
interpretation of the data, drafting of the manuscript, review and critique
of the statistical analysis and review and critique of the manuscript. WS
was involved in the conception and organization of this study and drafting,
review and critique of the manuscript. MY was involved in the execution
of the study, he reviewed and critiqued the statistical analysis plan and was
involved in the interpretation of the data and drafting, review and critique
of the manuscript. MCG was involved in the review and critique of the
statistical analysis, interpretation of the data and drafting, review and critique
of the manuscript. All authors take public responsibility for the content of
the manuscript. Each author agrees to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of any
part of work are appropriately investigated and resolved. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank Starr Grundy of SD Scientific for her assistance in preparation
of the manuscript. The study was funded by Isis Pharmaceuticals, Inc.
Author details
1Isis Pharmaceuticals, Inc, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
2Stanford University, 1000 Welch Rd Palo, Alto, CA 94304, USA.
Received: 17 July 2014 Accepted: 20 February 2015
References
1. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic
markers as indicators of disease progression and remission in rheumatoid
arthritis. Rheumatol Int. 2007;27:793–806.
2. Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE.
Complement activation in patients with rheumatoid arthritis mediated in
part by C-reactive protein. Arthritis Rheum. 2001;44:997–1002.
3. Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a
disease activity marker in rheumatoid arthritis. J Rheumatol. 2004;31:1095–7.
4. Jones NR, Pegues MA, McCrory MA, Singleton W, Bethune C, Baker BF, et al.
A selective inhibitor of human C-reactive protein translation is efficacious
in vitro and in C-reactive protein transgenic mice and humans. Mol Ther
Nucleic Acids. 2012;1:e52.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
6. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The
American College of Rheumatology 1991 revised criteria for the
classification of global functional status in rheumatoid arthritis. Arthritis
Rheum. 1992;35:498–502.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.
American College of Rheumatology. Preliminary definition of improvement
in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–35.
8. Prevoo ML, Van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,
van Riel PL. Modified disease activity scores that include twenty-eight-joint
counts. Development and validation in a prospective longitudinal study
of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
9. ISIS Pharmaceuticals Inc. Data on File. \\isis.local\ogroups\cdmstats\329993
\CS1\testdir\CohortIII\programs\thsCRPetCIII.sas DCHEN SASv9.2
(23MAR2011 14:13) Data Download: 21 March 2011.
